Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 17/20 | 0.82 |
| ▸ | CASP7 | P55210 | 10/20 | 0.82 |
| ▸ | CASP1 | P29466 | 5/20 | 0.60 |
| ▸ | CASP9 | P55211 | 3/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | CASP4 | P49662 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18471544 | 1.00 | CASP3 (0.82) | CASP3CASP7CASP1CASP9CTSL | |
| SCHEMBL18782287 | 0.94 | CASP3 (0.73) | CASP3CASP7CASP1CASP9CTSL | |
| SCHEMBL7887133 | 0.90 | CASP3 (1.00) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL18782311 | 0.90 | CASP3 (1.00) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL19015878 | 0.89 | CASP3 (0.66) | CASP3CASP7CASP1CASP9CTSL | |
| SCHEMBL7967979 | 0.89 | CASP3 (0.83) | CASP3CASP7CASP1CASP9CTSL | |
| SCHEMBL20609296 | 0.89 | CASP3 (0.83) | CASP3CASP7CASP1CASP9CTSL | |
| SCHEMBL18472220 | 0.87 | CASP3 (0.90) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL16375419 | 0.87 | CASP3 (0.90) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL12829828 | 0.85 | CASP3 (0.76) | CASP3CASP7CASP1CASP9CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10167313-B2 | Selective caspase inhibitors and uses thereof | GENESIS TECHNOLOGIES LIMITED (BB) | 2019-01-01 | — | — | US | disclosed |
| US-20170114092-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | GENESIS TECH LTD (BB) | 2017-04-27 | — | — | US | disclosed |
| US-9562069-B2 | Selective caspase inhibitors and uses thereof | NEW WORLD LABORATORIES INC. (CA) | 2017-02-07 | — | — | US | disclosed |
| US-9045524-B2 | Selective caspase inhibitors and uses thereof | NOVAGENESIS FOUNDATION (CH) | 2015-06-02 | — | — | US | disclosed |
| US-20150011458-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES INC. (CA) | 2015-01-08 | — | — | US | disclosed |
| US-8791235-B2 | Selective caspase inhibitors and uses thereof | NOVAGENESIS FOUNDATION (CH) | 2014-07-29 | — | — | US | disclosed |
| WO-2009140765-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES INC. (CA) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011458-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | CASP3, CASP1, HTRA2 | CASP3 1/4885CASP7 9/4885CASP1 2/4885 |
| US-20170114092-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP3, CASP5 | CASP3 2/4885CASP7 7/4885CASP1 1/4885 |
| US-10167313-B2 | Selective caspase inhibitors and uses thereof | CASP1, CASP3, CASP5 | CASP3 2/4885CASP7 7/4885CASP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.